(Q24185788)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

0 references

1 reference

title

Corticosteroids for the treatment of Duchenne muscular dystrophy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

Duchenne muscular dystrophy

4 April 2020

main subject

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

author name string

Emma Matthews

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Ruth Brassington

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Fatima Jichi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Adnan Y Manzur

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

publication date

5 May 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

4 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

page(s)

CD003725

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial

4 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Daily prednisone treatment in Duchenne muscular dystrophy in southwest China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

The role of corticosteroids in muscular dystrophy: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Deflazacort treatment of Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Deflazacort for the treatment of Duchenne Dystrophy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Remission of clinical signs in early duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Corticosteroids in Duchenne muscular dystrophy: major variations in practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing an

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Steroid therapy and cardiac function in Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Early prednisone treatment in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Corticosteroids in Duchenne muscular dystrophy: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Clinical investigation in duchenne dystrophy: 2. Determination of the ?power? of therapeutic trials based on the natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

145th ENMC International Workshop: planning for an International Trial of Steroid Dosage Regimes in DMD (FOR DMD), 22-24th October 2006, Naarden, The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

The PedsQL in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Pathophysiology of duchenne muscular dystrophy: current hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Prednisone in Duchenne dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

75th European Neuromuscular Centre International Workshop: 2nd workshop on the treatment of muscular dystrophy 10-12 December, 1999, Naarden, The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Prednisone for Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative/nitrosative stresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Population frequencies of inherited neuromuscular diseases—A world survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Clinical pharmacokinetics of prednisone and prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Clinical features and classification of the muscular dystrophies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Duchenne muscular dystrophy: prolongation of life by noninvasive ventilation and mechanically assisted coughing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Management of children: pharmacological and physical

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Cardioprotection for Duchenne's muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

The role of the dystrophin-glycoprotein complex in the molecular pathogenesis of muscular dystrophies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

The childhood muscular dystrophies: diseases sharing a common pathogenesis of membrane instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Modulation by prednisolone of calcium handling in skeletal muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Mechanical insufflation-exsufflation for people with neuromuscular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Cardiomyopathy in muscular dystrophies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy 24 January 2005, London, UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Dystrophin protects the sarcolemma from stresses developed during muscle contraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Prevention and treatment for cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Cyclosporine increases muscular force generation in Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Glucocorticoid corticosteroids for Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

Loss of strength and functional decline in Duchenne's dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Evidence-based path to newborn screening for Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

A synergistic effect of glucocorticoids and insulin on the differentiation of myoblasts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Clinical trial in Duchenne dystrophy. I. The design of the protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Deflazacort in Duchenne dystrophy: study of long-term effect

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Prednisone can protect against exercise-induced muscle damage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Steroids in duchenne muscular dystrophy — Deflazacort trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Predictive factors for the development of scoliosis in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Prednisone in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

The effect of methylprednisolone on intracellular calcium of normal and dystrophic human skeletal muscle cells

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Reference values of maximum isometric muscle force obtained in 270 children aged 4–16 years by hand-held dynamometry

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Steroids in muscular dystrophy: where do we stand?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

The muscular dystrophies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Long-Term Steroid Therapy in Duchenne Muscular Dystrophy-Positive Results versus Side Effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Prolongation of walking in Duchenne muscular dystrophy with lightweight orthoses: review of 57 cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Vertebral fractures in boys with Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Prevention of rapidly progressive scoliosis in Duchenne muscular dystrophy by prolongation of walking with orthoses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Long-term benefit from prednisone therapy in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Duchenne muscular dystrophy: quality of life among 95 patients evaluated using the Life Satisfaction Index for Adolescents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003725.PUB4

7 January 2021

10.1002/14651858.CD003725.PUB4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27149418%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1 reference